COVID vaccinations may be here to stay, at least for some people.
Moderna's chief executive said Monday (January 10) that annual boosters could be needed for certain groups.
That includes the over 50s and those with compromised immune systems.
The U.S. company says it's developing a booster shot targeted at the Omicron variant, and expects clinical trials to start soon.
Monday's comments came as Moderna updated its outlook for the year.
It now expects sales of COVID shots worth $18.5 billion in 2022.
The figure could yet increase by billions more though, if additional purchases including booster shots go ahead.
Moderna says it's in active discussions over further vaccine contracts.